Is COPN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of COPN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COPN (CHF61.4) is trading below our estimate of fair value (CHF784.1)
Significantly Below Fair Value: COPN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COPN?
Key metric: As COPN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for COPN. This is calculated by dividing COPN's market cap by their current
earnings.
What is COPN's PE Ratio?
PE Ratio
15.2x
Earnings
€69.57m
Market Cap
€1.06b
COPN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: COPN is good value based on its Price-To-Earnings Ratio (15.2x) compared to the European Pharmaceuticals industry average (20.2x).
Price to Earnings Ratio vs Fair Ratio
What is COPN's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
COPN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
15.2x
Fair PE Ratio
18.3x
Price-To-Earnings vs Fair Ratio: COPN is good value based on its Price-To-Earnings Ratio (15.2x) compared to the estimated Fair Price-To-Earnings Ratio (18.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst COPN forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
CHF 61.40
CHF 97.30
+58.5%
22.2%
CHF 132.49
CHF 78.92
n/a
4
Nov ’25
CHF 68.10
CHF 97.19
+42.7%
23.0%
CHF 133.30
CHF 76.59
n/a
4
Oct ’25
CHF 74.90
CHF 96.89
+29.4%
23.1%
CHF 132.99
CHF 76.32
n/a
4
Sep ’25
CHF 79.90
CHF 97.14
+21.6%
22.9%
CHF 132.96
CHF 76.63
n/a
4
Aug ’25
CHF 74.60
CHF 97.14
+30.2%
22.9%
CHF 132.96
CHF 76.63
n/a
4
Jul ’25
CHF 70.80
CHF 93.19
+31.6%
15.2%
CHF 112.82
CHF 78.44
n/a
4
Jun ’25
CHF 70.80
CHF 93.09
+31.5%
13.5%
CHF 109.09
CHF 79.54
n/a
4
May ’25
CHF 72.30
CHF 93.09
+28.8%
13.5%
CHF 109.09
CHF 79.54
n/a
4
Apr ’25
CHF 71.30
CHF 93.00
+30.4%
13.7%
CHF 109.38
CHF 79.27
n/a
4
Mar ’25
CHF 67.10
CHF 75.96
+13.2%
10.0%
CHF 83.49
CHF 65.58
n/a
3
Feb ’25
CHF 62.20
CHF 75.96
+22.1%
10.0%
CHF 83.49
CHF 65.58
n/a
3
Jan ’25
CHF 50.90
CHF 73.12
+43.7%
11.3%
CHF 84.75
CHF 66.58
n/a
3
Dec ’24
CHF 42.75
CHF 73.36
+71.6%
10.7%
CHF 84.41
CHF 67.77
CHF 63.20
3
Nov ’24
CHF 35.20
CHF 73.97
+110.1%
10.6%
CHF 85.09
CHF 68.37
CHF 68.10
3
Oct ’24
CHF 39.90
CHF 73.97
+85.4%
10.6%
CHF 85.09
CHF 68.37
CHF 74.90
3
Sep ’24
CHF 44.55
CHF 68.10
+52.9%
17.2%
CHF 85.12
CHF 52.03
CHF 79.90
4
Aug ’24
CHF 44.80
CHF 74.16
+65.5%
10.1%
CHF 85.55
CHF 66.89
CHF 74.60
4
Jul ’24
CHF 45.25
CHF 77.41
+71.1%
7.9%
CHF 85.09
CHF 67.97
CHF 70.80
4
Jun ’24
CHF 47.00
CHF 80.45
+71.2%
12.9%
CHF 96.55
CHF 67.59
CHF 70.80
4
May ’24
CHF 53.90
CHF 80.45
+49.3%
12.9%
CHF 96.55
CHF 67.59
CHF 72.30
4
Apr ’24
CHF 56.80
CHF 81.83
+44.1%
12.6%
CHF 97.03
CHF 67.93
CHF 71.30
4
Mar ’24
CHF 60.30
CHF 81.70
+35.5%
12.8%
CHF 97.22
CHF 67.99
CHF 67.10
4
Feb ’24
CHF 67.40
CHF 83.59
+24.0%
12.3%
CHF 99.80
CHF 71.50
CHF 62.20
4
Jan ’24
CHF 61.20
CHF 83.61
+36.6%
13.7%
CHF 98.40
CHF 70.50
CHF 50.90
3
Dec ’23
CHF 62.80
CHF 84.07
+33.9%
16.5%
CHF 97.95
CHF 70.18
CHF 42.75
2
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.